drugset / Trial / NCT06340048
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
Phase 1/2
Active not recruiting
36 enrolled
HELP Therapeutics Co., Ltd.
TEDA International Cardiovascular Hospital · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this clinical study is to evaluate the feasibility, safety and efficacy of intramyocardial injection of human induce pluripotent stem cell-derived cardiomyocytes (HiCM-188) during coronary artery bypass grafting (CABG) surgery in patients with severe chronic ischemic heart failure.
Timeline
- Start
- 2023-09-05
- Primary completion
- 2026-11-10
- Completion
- 2027-05-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HiCM-188 | Cell therapy | 5e+07 cells | Other |
| Subject | HiCM-188 | Cell therapy | 1.5e+08 cells | Other |
| Subject | HiCM-188 | Cell therapy | 4.5e+08 cells | Other |